- Home
- CVM vs ATOS Comparison
CVM vs ATOS Comparison
Compare CVM & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVM | ATOS |
|---|---|---|
| Founded | 1983 | 2009 |
| Country | United States | United States |
| Employees | 44 | 14 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.1M | 24.1M |
| IPO Year | 1996 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CVM | ATOS |
|---|---|---|
| Price | $1.69 | $2.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | ★ 319.2K | 64.1K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $264,033.00 | $1,758.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 65.45 | N/A |
| 52 Week Low | $0.89 | $0.53 |
| 52 Week High | $13.48 | $7.56 |
Technical Indicators
Market Signals| Indicator | CVM | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 68.91 | 48.98 |
| Support Level | $0.95 | $0.58 |
| Resistance Level | $1.86 | $2.60 |
| Average True Range (ATR) | 0.11 | 0.15 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 98.04 | 67.27 |
Price Performance
Historical ComparisonAbout CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.